Weekly Digest - 15-21 Apr 2023

Weekly Digest - 15-21 Apr 2023

April 16, 2023: Durvalumab (IV) / NSCLC / AstraZeneca: Results from Phase 3 AEGEAN study demonstrated prolong event-free survival

  • AstraZeneca reported data from AACR 2023 for Phase 3 AEGEAN trial evaluating Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab in patients with NSCLC

  • Durvalumab regimen led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) and pathologic complete response (pCR)

    • Imfinzi-based regimen before and after surgery showed a 32% reduction in the risk of recurrence, progression events or death versus chemotherapy alone
    • Durvalumab plus Neoadjuvant chemotherapy before surgery resulted in a pCR rate of 17.2% vs 4.3% for patients treated with Neoadjuvant chemotherapy alone
  • The AEGEAN trial shows this novel Imfinzi-based regimen meaningfully improved outcomes in resectable lung cancer. We look forward to discussing these data with global regulatory authorities with the goal of providing this important new treatment option to patients” said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca 

For full story click here

Share this